(Total Views: 627)
Posted On: 10/30/2024 8:57:56 AM
Post# of 148863
Quote:
Dr. Palmer will work with the CytoDyn team to oversee the two follow-up studies with SMC. These studies will again compare leronlimab alone and in combination with other therapies, including both resmetirom, the only approved treatment for MASH, and a GLP-1 agonist in an increased number of mice evaluated in both a proprietary STAM model of MASH which includes T2DM (previously studied), as well as a second model of liver fibrosis driven by CCL4 toxicity that is independent of fat deposition.
Getting all the background work done to show what leronlimab is capable of.
(19)
(0)Scroll down for more posts ▼
